Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
September 2023
in “Dermatology and Therapy”
TLDR Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
The document is a post-hoc analysis of two phase 3 trials, BRAVE-AA1 and BRAVE-AA2, involving 855 patients, studying the efficacy of Baricitinib, an oral JAK1/JAK2 inhibitor, in treating severe alopecia areata (AA). The study found that both 2 mg and 4 mg doses of Baricitinib improved scalp hair growth up to week 52. Patients with a Severity of Alopecia Tool (SALT) score of 50-94 responded better than those with a score of 95-100. The 4 mg dose resulted in a faster and higher response rate than the 2 mg dose. However, patients with a baseline SALT score of 95-100 had a longer response time to treatment. The study concluded that the baseline severity of hair loss should be considered when setting expectations about treatment response.
View this study on link.springer.com →
Cited in this study
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research Alopecia areata – Current understanding and management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Rethinking The Classification Of Alopecia Areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research The Medical and Psychosocial Associations of Alopecia: Recognizing Hair Loss as More Than a Cosmetic Concern
Alopecia is linked to various health and mental conditions, impacts life quality, and needs medical attention beyond its cosmetic effects.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
Related
research Twenty nail dystrophy with alopecia areata in an atopic child
A child with rough nails also had hair loss and allergies.